Victory Capital Management Inc. Sells 123,296 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)

Victory Capital Management Inc. lowered its position in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 35.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 223,062 shares of the company's stock after selling 123,296 shares during the quarter. Victory Capital Management Inc. owned approximately 0.50% of Apogee Therapeutics worth $10,105,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Apogee Therapeutics during the 3rd quarter worth about $71,000. Wexford Capital LP bought a new stake in shares of Apogee Therapeutics during the 3rd quarter worth about $230,000. Intech Investment Management LLC bought a new stake in shares of Apogee Therapeutics during the 3rd quarter worth about $300,000. Valence8 US LP bought a new stake in shares of Apogee Therapeutics during the 3rd quarter worth about $308,000. Finally, FORA Capital LLC bought a new stake in shares of Apogee Therapeutics during the 3rd quarter worth about $399,000. Hedge funds and other institutional investors own 79.04% of the company's stock.

Insider Buying and Selling at Apogee Therapeutics

In other news, CEO Michael Thomas Henderson sold 10,000 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $30.15, for a total value of $301,500.00. Following the sale, the chief executive officer now directly owns 1,292,987 shares in the company, valued at approximately $38,983,558.05. This represents a 0.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Carl Dambkowski sold 1,590 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $30.48, for a total value of $48,463.20. Following the completion of the sale, the insider now owns 251,033 shares in the company, valued at approximately $7,651,485.84. This represents a 0.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 49,195 shares of company stock valued at $2,026,392 in the last quarter. Corporate insiders own 36.10% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several analysts have recently issued reports on APGE shares. Canaccord Genuity Group started coverage on Apogee Therapeutics in a research note on Monday, November 25th. They set a "buy" rating and a $89.00 price target for the company. Citigroup started coverage on Apogee Therapeutics in a research report on Thursday. They set a "buy" rating and a $95.00 price objective for the company. Guggenheim reissued a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Canaccord Genuity Group started coverage on Apogee Therapeutics in a research report on Monday, November 25th. They set a "buy" rating and a $89.00 price objective for the company. Finally, Wedbush reissued an "outperform" rating and set a $90.00 price objective on shares of Apogee Therapeutics in a research report on Tuesday, March 11th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Apogee Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $92.17.

Apogee Therapeutics Stock Up 4.2 %

Apogee Therapeutics stock traded up $1.61 during trading hours on Friday, hitting $39.94. The stock had a trading volume of 665,998 shares, compared to its average volume of 479,296. The company has a 50-day moving average of $38.21 and a two-hundred day moving average of $46.59. The company has a market cap of $1.80 billion, a PE ratio of -16.50 and a beta of 2.46. Apogee Therapeutics, Inc. has a fifty-two week low of $29.10 and a fifty-two week high of $71.75.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($1.19) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.25). As a group, analysts forecast that Apogee Therapeutics, Inc. will post -3.09 EPS for the current fiscal year.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.